Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • caswater
    Member
    • Jun 2011
    • 47

    #1

    question about exon usage across conditions?

    Hi,

    I want to quantify exon inclusion/skipping rates across a number of different conditions. So for each condition, I obtained FPKM values for each exon, and also FPKMs for each gene locus encompassing all the eons. Does it make sense if I use the ratio of EXON-FPKM/Gene-FPKM in each condition to quantify the exon usage in the condition?

    Thank you
  • Brian Bushnell
    Super Moderator
    • Jan 2014
    • 2709

    #2
    Yes, it seems logical to me.

    Comment

    • dpryan
      Devon Ryan
      • Jul 2011
      • 3478

      #3
      So one notable problem with this approach is if you get a bit of a different mapping distribution between the groups (i.e., more/less 5' bias) then the results will be off. If you wanted to look at straight differential exon usage, you could just use DEXseq. If you wanted to specifically look at differential exon skipping, a good method would be (in this case, looking at skipping of exon #2):
      1. Count the number of reads mapping from exon 1 to exon 2
      2. Count the number of reads mapping from exon 1 to exon 3
      3. Fit these counts with a beta-binomial model (this is the same as is increasingly used to look at bisulfite sequencing and is the most relevant model for the type of data you have).


      There are a couple packages to do that with R, though I can't guarantee that they're pretty limited in terms of model complexity. If you need something that can handle more than 2 groups, just let me know, since I'm writing a package to do that (for methylation data, but the statistics are the same).

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
        by SEQadmin2



        Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

        Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
        ...
        10-14-2026, 09:55 AM
      • SEQadmin2
        New Genomics Technologies Take Aim at Long-Standing Limits
        by SEQadmin2


        Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

        We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
        ...
        09-28-2026, 10:25 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 10-22-2026, 11:13 AM
      0 responses
      27 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-22-2026, 10:48 AM
      0 responses
      20 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-15-2026, 10:52 AM
      0 responses
      38 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-14-2026, 05:39 AM
      0 responses
      44 views
      0 reactions
      Last Post SEQadmin2  
      Working...